Upfront Transplant Prevails Again in Newly Diagnosed Myeloma

(MedPage Today) -- An immunomodulatory-free carfilzomib (Kyprolis)-based triplet regimen failed to prove non-inferior to autologous hematopoietic stem-cell transplantation (HSCT) for the upfront treatment of newly diagnosed multiple myeloma, a...
Source: MedPage Today Surgery - Category: Surgery Source Type: news